comparemela.com

Latest Breaking News On - Maria tortoreto - Page 1 : comparemela.com

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl...

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl...
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Canada
United-kingdom
Michigan
United-states
American
Maria-tortoreto
Steven-pascoe
Etanjalie-ayala
European-union
Behring-pharmacovigilance-department
Drug-administration
European-commission

CSL and uniQure Win 2023 Prix Galien USA Award

CSL and uniQure Win 2023 Prix Galien USA Award
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada
Australia
United-states
United-kingdom
Tom-malone
Jimmy-baker
Prix-galien
Matt-kapusta
Etanjalie-ayala
Kim-odonohue
Maria-tortoreto
Mariae-cantor

Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B

CSL s HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis OTTAWA, ON, Oct. 26, 2023 /CNW/ Global biotechnology leader CSL today announced.

Australia
Ottawa
Ontario
Canada
United-states
United-kingdom
American
Maria-tortoreto
Philippe-hebert
Jimmy-baker
Etanjalie-ayala
Kim-odonohue

CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment

/PRNewswire/ Global biotechnology leader CSL (ASX: CSL) today announced the presentation of data affirming the long-term durability and safety of.

United-states
Michigan
American
Etanjalie-ayala
Maria-tortoreto
American-society-of-hematology
Twitter
Drug-administration
Operations-communications
Behring-pharmacovigilance-department
University-of-michigan
Wrd-communications

CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr...

Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduc.

United-states
Michigan
American
Etanjalie-ayala
Maria-tortoreto
American-society-of-hematology
Twitter
Drug-administration
Operations-communications
Behring-pharmacovigilance-department
University-of-michigan
Wrd-communications

vimarsana © 2020. All Rights Reserved.